Significant Investment Expansion CordenPharma is making a record investment of over €1 billion in building and expanding peptide manufacturing facilities across Europe and the US, indicating a strong commitment to scaling production capabilities and attracting clients needing large-scale peptide and API manufacturing services.

Strategic Facility Development The company is establishing state-of-the-art, greenfield manufacturing facilities in Switzerland and the US, presenting opportunities to offer advanced manufacturing solutions, technical support, and collaborative development partnerships to biotech and pharma clients.

Recent Industry Collaborations Partnering with Viking Therapeutics, a clinical-stage biotech company, highlights CordenPharma’s focus on peptide-based therapeutics and opens doors to engage with emerging biotech firms and early-stage developers seeking specialized manufacturing expertise.

Market Focus and Capabilities CordenPharma's broad technology platform offerings including peptides, lipids, oligonucleotides, and highly potent compounds indicate a versatile service portfolio tailored to innovative pharmaceutical companies looking for comprehensive development and manufacturing solutions.

Regional Growth Potential With expansions in Basel, Boulder, and across Europe and the US, CordenPharma is positioned for increased market penetration in key biotech hubs, presenting opportunities to target regional pharma and biotech firms seeking reliable, large-scale CDMO services.